pharmaceutical investing Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA
pharmaceutical investing Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xerava as a Treatment for Complicated Intra-Abdominal Infections
pharmaceutical investing Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results
pharmaceutical investing Tetraphase Pharmaceuticals Announces FDA Acceptance for Filing of its NDA Submission for Eravacycline
pharmaceutical investing Tetraphase Pharmaceuticals Enters into Exclusive Development and Commercialization Agreement with Everest Medicines
pharmaceutical investing Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
